期刊
CANCER AND METASTASIS REVIEWS
卷 36, 期 4, 页码 655-668出版社
SPRINGER
DOI: 10.1007/s10555-017-9701-1
关键词
Proteasome; Deubiquitinase; Metal; DUB inhibitor; Cancer
类别
资金
- National High Technology Research and Development Program of China [2006AA02Z4B5]
- NSFC [81272451/H1609, 81472762/H1609]
- US National Institutes of Health [R01GM115366, R01CA160417]
- Natural Science Foundation of Guangdong Province [2016A030308011]
- American Cancer Society [RSG-16-014-01-CDD]
- National Natural Science Foundation of China [31671435]
Deubiquitinases (DUBs) play an important role in protein quality control in eukaryotic cells due to their ability to specifically remove ubiquitin from substrate proteins. Therefore, recent findings have focused on the relevance of DUBs to cancer development, and pharmacological intervention on these enzymes has become a promising strategy for cancer therapy. In particular, several DUBs are physically and/or functionally associated with the proteasome and are attractive targets for the development of novel anticancer drugs. The successful clinical application of cisplatin in cancer treatment has prompted researchers to develop various metal-based anticancer agents with new properties. Recently, we have reported that several metal-based drugs, such as the antirheumatic gold agent auranofin (AF), the antifouling paint biocides copper pyrithione (CuPT) and zinc pyrithione (ZnPT), and also our two synthesized complexes platinum pyrithione (PtPT) and nickel pyrithione (NiPT), can target the proteasomal DUBs UCHL5 and USP14. In this review, we summarize the recently reported small molecule inhibitors of proteasomal DUBs, with a focus on discussion of the unique nature of metal-based proteasomal DUB inhibitors and their anticancer activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据